Navigation Links
Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity
Date:2/17/2009

OSAKA, Japan and FLORHAM PARK, N.J., Feb. 17 /PRNewswire/ -- Shionogi & Co, Ltd. today announced that two distinct year-long studies of velneperit, a novel neuropeptide Y (NPY) Y5 receptor antagonist also known as S-2367, each met their primary endpoint of demonstrating a statistically significant reduction in body weight. These clinical studies further demonstrate the potential for the NPY Y5 receptor as a target for obesity treatment.

Shionogi assessed the long term efficacy and safety of velneperit over the course of one year in two distinct studies, comprising a total randomized population of 1,566 obese subjects across 80 centers in the United States. Each respective study assessed the efficacy and safety of velneperit under different reduced calorie diet and low calorie diet conditions. In the strongest performing group relative to placebo across the two studies, subjects undergoing velneperit treatment of 800mg once-daily in combination with a reduced calorie diet responded with 5% or greater weight loss at a percentage nearly three times higher than those on placebo (35% vs. 12%). In addition, velneperit treatment resulted in statistically significant differences with respect to secondary parameters such as decreased waist circumference and improved serum lipid profile. In terms of safety, velneperit was well tolerated in all groups over the course of one year treatment, a finding consistent with subject experience in previous clinical studies. A full analysis of the current study data, including secondary efficacy endpoints as well as safety and laboratory parameters is currently underway.

Study Design and Results

Two distinct double-blind, placebo controlled trials were employed to examine the safety and effectiveness of long-term velneperit treatment under different diet conditions. The unique mechanism of action of velneperit involves blocking the Y5 binding receptor for neurope
'/>"/>

SOURCE Shionogi & Co., Ltd.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. Bayer/Schering-Plough/Shionogis Avelox Has Advantages Over Levofloxacin in the Treatment of Community-Acquired Pneumonia
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
5. HEI, Inc. Announces Sale of RFID Division Assets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brooke Franchise Corporation Announces Selected July Results
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Dallas, Texas (PRWEB) May 21, 2013 ... based on product type into two categories - ... AED market is classified into five categories, namely, ... the market is forecast till 2017. Automated external ... lives of sudden cardiac arrest victims. Considering the ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 When ... it's not always to become a celebrity. New ... 7, 2013 ABC News report (“Chris Christie Says ... it clear that the surgery was not done ... or gain celebrity status as a former lap ...
(Date:5/20/2013)... May 20, 2013 Fastcare Miami Beach ... infection (UTI) within its first symptoms, as if not treated, ... a more serious infection. Although a urinary tract infection in ... lead to serious kidney infection called pyelonephritis. Women seem to ... come up to the same percentage as women after the ...
(Date:5/20/2013)... Denver, Colorado (PRWEB) May 20, 2013 Daily ... willing to provide its readers with useful tips that can ... vitiligo. , According to the website Natural Vitiligo ... due to the numerous positive reviews it has received from ... a secret until now, but Daily Gossip has interviewed some ...
(Date:5/20/2013)... May 20, 2013 Parker Waichman LLP, ... of victims injured by defective drugs, has filed a ... alleges that use of the diabetes drug medication ... filed on April 30, 2013, in the U.S. District ... 6:13-cv-0888), where it is one of thousands of cases ...
Breaking Medicine News(10 mins):Health News:North America Leads Automated External Defibrillator Market (AED), Says New Research Report at ReportsnReports.com 2Health News:North America Leads Automated External Defibrillator Market (AED), Says New Research Report at ReportsnReports.com 3Health News:The Lap Band Center: Dr. Atul Madan Applauds Chris Christie's Dedication to Family and Loss of 30 Pounds After Lap Band Surgery 2Health News:The Lap Band Center: Dr. Atul Madan Applauds Chris Christie's Dedication to Family and Loss of 30 Pounds After Lap Band Surgery 3Health News:Fastcare Advises on How to Prevent a UTI 2Health News:New Natural Vitiligo Treatment System That Helps People Treat Vitiligo Permanently Revealed by Daily Gossip Magazine 2Health News:Taking Actos for Two Years Caused Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP on Behalf of South Dakota Man 2
... less useful, but some experts disagree , , MONDAY, March ... undermined the value of the prostate-specific antigen (PSA) test ... study asserts. , However, that assertion was immediately challenged ... Cancer Society recommends annual screening for prostate cancer for ...
... Inc. (Nasdaq: MLNM ) today announced that ... Healthcare Conference will be webcast,live and may be ... Company,s,website, http://www.millennium.com ., (Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO ... update on VELCADE(R) (bortezomib) for,Injection and product candidates ...
... Cadient campaigns nominated for Best Non-Branded Web site, Best ... Web site, and Best Digital Media Campaign, WEST ... interactive marketing agency serving the healthcare,industry, announced today it ... Awards. Award winners will be announced at the DTC,National ...
... (http://www.NBTY.com ), a leading global manufacturer and marketer ... the,presentation by Harvey Kamil, President and Chief Financial Officer ... New York on Tuesday,March 11, 2008., The presentation ... Company Web,site, http://www.nbty.com on Tuesday, March 11, ...
... DENVER, March 10 Tea-based ingredients are ... and Colorado-based Sage,Group(R), a self-described ,tea think-tank, ... now outnumber beverage,tea offerings on a global ... and other tea derivatives are being formulated ...
... WILLISTON, Vt., March 10 Laborie Medical Technologies,today ... given clearance to proceed with marketing efforts for ... the US Food and Drug Administration,(USFDA)., Laborie ... its internationally-recognized quality system (ISO-13485) so that,TETRA(TM) can ...
Cached Medicine News:Health News:PSA Test Losing Diagnostic Value, Study Says 2Health News:PSA Test Losing Diagnostic Value, Study Says 3Health News:Cowen & Company 28th Annual Healthcare Conference to Webcast Millennium Presentation 2Health News:Cadient Group Receives Multiple Nominations for 2008 DTC National Advertising Awards 2Health News:NBTY to Webcast Presentation at Bank of America Consumer Conference: Announces Preliminary Sales and the Repurchase of 6.1 Million Shares 2Health News:NBTY to Webcast Presentation at Bank of America Consumer Conference: Announces Preliminary Sales and the Repurchase of 6.1 Million Shares 3Health News:Tea Ingredients Publication Serves Robust Global Demand for Tea-Based Products 2Health News:Tea Ingredients Publication Serves Robust Global Demand for Tea-Based Products 3Health News:Laborie Medical Technologies Receives FDA Pre-Market Clearance for TETRA(TM)- NIRS Accessory for the US Market 2
(Date:5/20/2013)... , LONDON , ... May 20, 2013 Arthroscopy ... Osteoarthritis and Preference for Minimally Invasive Procedures to Drive ... and market trends for the six arthroscopy device market ... arthroscopy implants, arthroscopy radio frequency systems, and arthroscopy visualization ...
(Date:5/20/2013)... 20, 2013  Neuralstem, Inc. (NYSE MKT: CUR) today ... PhD, principal investigator, presented updated Phase I data from ... in the treatment of amyotrophic lateral sclerosis (ALS or ... neuro diabetes special medical symposium in Bucharest, ... "Recent Therapeutic Advances in Stem Cell Therapy," Dr. Feldman ...
(Date:5/20/2013)... With herbal medicines relied upon by consumers ... Pharmacopeial Convention (USP) will provide freely available public standards ... used in these products. Today, USP proposes the first ... Herbal Medicines Compendium ( HMC ) for comment ... . HMC will provide standards for ...
Breaking Medicine Technology:Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 2Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 3Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 4Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4New Compendium Offers Freely Available Testing Standards to Help Ensure the Quality of Herbal Ingredients Used in Traditional Medicines 2New Compendium Offers Freely Available Testing Standards to Help Ensure the Quality of Herbal Ingredients Used in Traditional Medicines 3
... LOS ANGELES, Oct. 24, 2011 NeuroSigma, Inc., a ... has signed a contract with the University of California, ... clinical trial to study the use of non-invasive, external ... Deficit Hyperactivity Disorder (ADHD).  NeuroSigma is the exclusive worldwide ...
... HealthWarehouse.com, Inc. (OTC: HEWA), a leading VIPPS-accredited ... begin providing prescription medications for WhiteGlove Health, Inc., ... excited to have a national partner to provide ... Robert Fabbio, co-founder and chief executive officer of ...
Cached Medicine Technology:NeuroSigma Funds First-Ever Pediatric Clinical Trial to Study Non-Invasive External Trigeminal Nerve Stimulation for the Treatment of ADHD 2NeuroSigma Funds First-Ever Pediatric Clinical Trial to Study Non-Invasive External Trigeminal Nerve Stimulation for the Treatment of ADHD 3WhiteGlove Health Selects HealthWarehouse.com to Provide Prescription Medications to its Members Nationwide 2
The WaveMap provides immediate clinical decision making information with automatic calculation of pressure gradients and FFR measurements.,SmartWire Pressure Guide Wire - The intelligent choice in ...
... for vascular access. Hollow stylet ... wall puncture with two-part needle. ... visualized while maintaining thumb position ... the hub of the stylet. ...
Used for placement of .035 inch (0.89 mm) or .038 inch (0.97 mm) diameter wire guides into the vascular system when a small 24 gage needle stick is desired....
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Medicine Products: